Femasys (NASDAQ:FEMY) and Carmell (NASDAQ:CTCX) Financial Review

Carmell (NASDAQ:CTCXGet Free Report) and Femasys (NASDAQ:FEMYGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Earnings and Valuation

This table compares Carmell and Femasys’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Carmell N/A N/A -$15.44 million N/A N/A
Femasys $1.05 million 24.99 -$14.25 million ($0.84) -1.40

Femasys has higher revenue and earnings than Carmell.

Volatility & Risk

Carmell has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.79, indicating that its share price is 379% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Carmell and Femasys, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carmell 0 0 0 0 N/A
Femasys 0 0 3 0 3.00

Femasys has a consensus target price of $11.67, suggesting a potential upside of 888.70%. Given Femasys’ higher possible upside, analysts plainly believe Femasys is more favorable than Carmell.


This table compares Carmell and Femasys’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Carmell N/A -171.27% -22.94%
Femasys -1,420.59% -104.06% -73.32%

Institutional & Insider Ownership

24.2% of Carmell shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 16.4% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


Femasys beats Carmell on 7 of the 10 factors compared between the two stocks.

About Carmell

(Get Free Report)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

About Femasys

(Get Free Report)

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.